AU2007313684A1 - PAI-1 binding modulators for the treatment of ocular disorders - Google Patents

PAI-1 binding modulators for the treatment of ocular disorders Download PDF

Info

Publication number
AU2007313684A1
AU2007313684A1 AU2007313684A AU2007313684A AU2007313684A1 AU 2007313684 A1 AU2007313684 A1 AU 2007313684A1 AU 2007313684 A AU2007313684 A AU 2007313684A AU 2007313684 A AU2007313684 A AU 2007313684A AU 2007313684 A1 AU2007313684 A1 AU 2007313684A1
Authority
AU
Australia
Prior art keywords
pai
agent
volume
percent weight
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007313684A
Other languages
English (en)
Inventor
Abbot Clark
Debra Fleenor
Iok-Hou Pang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Research LLC
Original Assignee
Alcon Research LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Research LLC filed Critical Alcon Research LLC
Publication of AU2007313684A1 publication Critical patent/AU2007313684A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2007313684A 2006-10-31 2007-10-31 PAI-1 binding modulators for the treatment of ocular disorders Abandoned AU2007313684A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86371506P 2006-10-31 2006-10-31
US60/863,715 2006-10-31
PCT/US2007/083170 WO2008055205A2 (en) 2006-10-31 2007-10-31 Pai-1 binding modulators for the treatment of ocular disorders

Publications (1)

Publication Number Publication Date
AU2007313684A1 true AU2007313684A1 (en) 2008-05-08

Family

ID=39345074

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007313684A Abandoned AU2007313684A1 (en) 2006-10-31 2007-10-31 PAI-1 binding modulators for the treatment of ocular disorders

Country Status (11)

Country Link
US (2) US20080107644A1 (enExample)
EP (1) EP2077829A2 (enExample)
JP (1) JP2010508306A (enExample)
KR (1) KR20090082401A (enExample)
CN (1) CN101588798A (enExample)
AU (1) AU2007313684A1 (enExample)
CA (1) CA2666316A1 (enExample)
MX (1) MX2009004792A (enExample)
RU (1) RU2465898C2 (enExample)
WO (1) WO2008055205A2 (enExample)
ZA (1) ZA200902453B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090202524A1 (en) * 2007-10-31 2009-08-13 Alcon Research, Ltd. Pai-1 expression and activity inhibitors for the treatment of ocular disorders
US20100158897A1 (en) * 2006-10-31 2010-06-24 Alcon Research, Ltd. Pai-1 modulators for the treatment of ocular disorders
JP5924625B2 (ja) * 2011-11-15 2016-05-25 国立大学法人浜松医科大学 プラスミノゲンアクチベータインヒビター−１による流産、早産治療薬
US10946076B2 (en) 2013-02-13 2021-03-16 The Research Foundation For The State University Of New York Glaucoma treatment
US9820954B2 (en) * 2015-08-19 2017-11-21 Jenivision Inc. Quantitative peri-orbital application of ophthalmology drugs

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9306399A (pt) * 1992-05-22 1998-09-15 Senju Pharma Co Composição farmacéutica para uso no tratamento de glaucoma
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
EA004050B1 (ru) * 1998-12-11 2003-12-25 Бакулиш Мафатлал Хамар Способ изготовления состава местных бета-блокаторов улучшенного действия
AU771635B2 (en) * 1999-01-05 2004-04-01 American National Red Cross, The Methods for treating conditions associated with the accumulation of excess extracellular matrix
CA2476761A1 (en) * 2002-02-19 2003-08-28 Vanderbilt University Therapeutic methods employing pai-1 inhibitors and transgenic non-human animal for screening candidate pai-1 inhibitors
EP1497420A4 (en) * 2002-04-30 2005-04-27 Alcon Inc AGENTS THAT REGULATE, RESTRICT OR MODULATE THE ACTIVITY AND / OR EXPRESSION OF BIND WEAVE GROWTH FACTOR (CTGF) AS UNIQUE MEDICAMENTS BOTH TO REDUCE EYESPRINTS AND TREAT GLACCOMPETOSIS RETINOPATHIES / OPTIC NEUROPATHIES

Also Published As

Publication number Publication date
RU2465898C2 (ru) 2012-11-10
US20080107644A1 (en) 2008-05-08
MX2009004792A (es) 2009-05-21
WO2008055205A2 (en) 2008-05-08
EP2077829A2 (en) 2009-07-15
ZA200902453B (en) 2010-07-28
RU2009120545A (ru) 2010-12-10
CA2666316A1 (en) 2008-05-08
CN101588798A (zh) 2009-11-25
KR20090082401A (ko) 2009-07-30
JP2010508306A (ja) 2010-03-18
WO2008055205A3 (en) 2008-07-17
US20100260784A1 (en) 2010-10-14

Similar Documents

Publication Publication Date Title
CN100425241C (zh) 由Rho激酶抑制剂和前列腺素类物质构成的青光眼治疗剂
JP4934653B2 (ja) Ｒｈｏキナーゼ阻害剤とβ遮断薬からなる緑内障治療剤
US20100260784A1 (en) Pai-1 binding modulators for the treatment of ocular disorders
JP4482726B2 (ja) Ｒｈｏキナーゼ阻害剤とプロスタグランジン類からなる緑内障治療剤
WO2008079980A1 (en) Inhibitors of protein kinase c-delta for the treatment of glaucoma
US20110105574A1 (en) Pai-1 expression and activity inhibitors for the treatment of ocular disorders
US20100158897A1 (en) Pai-1 modulators for the treatment of ocular disorders
WO2009061721A1 (en) Complement c1q inhibitors for the prevention and treatment of glaucoma
US20090181896A1 (en) Use of Natriuretic Peptide Receptor Antagonists to Treat Ocular, Otic and Nasal Edemetous Conditions
AU2007234903B2 (en) Prenyltransferase inhibitors for ocular hypertension control and the treatment of glaucoma
US6534475B1 (en) Use of TIMP-3 inducers of TIMP-3 expression, and TIMP-3 mimetics to treat ocular neovascularization

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application